Belvedere Trading
PTGX icon

Belvedere Trading’s Protagonist Therapeutics PTGX Stock Holding History

Belvedere Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$9K – 1005
2024
Q3 		$9K Sell
200
-2,300
-92% -$92.9K ﹤0.01% 641
2024
Q2 		$86.6K Buy
+2,500
New +$73.2K ﹤0.01% 454
2023
Q3 		– Sell
-1,900
Closed -$52.5K – 885
2023
Q2 		$52.5K Sell
1,900
-3,000
-61% -$75.1K ﹤0.01% 540
2023
Q1 		$113K Buy
+4,900
New +$82.3K ﹤0.01% 456
2022
Q3 		– Sell
-3,600
Closed -$37K – 378
2022
Q2 		$37K Buy
+3,600
New +$43.5K ﹤0.01% 309
2021
Q4 		– Sell
-300
Closed -$9K – 584
2021
Q3 		$9K Buy
+300
New +$12.8K ﹤0.01% 462

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Belvedere Trading's PTGX Position: Q2 2023 in Review

Belvedere Trading sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 24,011 shares — an estimated $601K sold.

Belvedere Trading first reported a position in PTGX in Q3 2021 and held it in 3 quarters. The position peaked at $552K in Q1 2023. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • Belvedere Trading reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 24,011 Protagonist Therapeutics shares in Q2 2023, an estimated $601K.
  • Belvedere Trading first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 3 quarters.
  • Belvedere Trading's Protagonist Therapeutics position peaked at $552K in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.